Cingapura - inglês - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - salbutamol sulphate eqv salbutamol - solution - 2.5 mg - salbutamol sulphate eqv salbutamol 2.5 mg

Cingapura - inglês - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - salbutamol sulphate eqv salbutamol - injection - 5 mg/5 ml - salbutamol sulphate eqv salbutamol 5 mg/5 ml

Cingapura - inglês - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - hepatitis b surface antigen protein (yeast) - injection - 10 mcg/0.5 ml - hepatitis b surface antigen protein (yeast) 10 mcg/0.5 ml

Cingapura - inglês - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - epoprostenol - injection, powder, for solution - 0.5 mg/vial - epoprostenol 0.5 mg/vial

Cingapura - inglês - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - ceftazidime pentahydrate eqv ceftazidime - injection, powder, for solution - 1 g/vial - ceftazidime pentahydrate eqv ceftazidime 1 g/vial

Cingapura - inglês - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - human rotavirus, live, attenuated, rix 4414 strain - suspension - not less than 10⁶ ccid₅₀/dose (1.5 ml) - human rotavirus, live, attenuated, rix 4414 strain not less than 10⁶ ccid₅₀/dose (1.5 ml)

Cingapura - inglês - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - conjugate of streptococcus pneumoniae type 1 & haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 14 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 18c and tetanus toxoid; conjugate of streptococcus pneumoniae type 19f and diphtheria toxoid; conjugate of streptococcus pneumoniae type 23f and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 4 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 5 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 6b and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 7f and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 9v and haemophilus influenzae protein d; diphtheria toxoid (dt) carrier protein; polysaccharide (ps); protein-d (pd) carrier protein (derived from non-typeable haemophilus influenzae); tetanus toxoid (tt) carrier protein - injection, suspension - 1 μg ps1; 1.11-1.67 μg pd/dose - conjugate of streptococcus pneumoniae type 1 & haemophilus influenzae protein d 1 μg ps1; 1.11-1.67 μg pd/dose; conjugate of streptococcus pneumoniae type 14 and haemophilus influenzae protein d 1 μg ps14; 1.00-1.82 μg pd/dose; conjugate of streptococcus pneumoniae type 18c and tetanus toxoid 3 μg ps18c; 5.45-10.00 μg tt/dose; conjugate of streptococcus pneumoniae type 19f and diphtheria toxoid 3 μg ps19f; 3.33-6.00 μg dt/dose; conjugate of streptococcus pneumoniae type 23f and haemophilus influenzae protein d 1 μg ps23f; 0.39-0.74 μg pd/dose; conjugate of streptococcus pneumoniae type 4 and haemophilus influenzae protein d 3 μg ps4; 3.33-6.67 μg pd/dose; conjugate of streptococcus pneumoniae type 5 and haemophilus influenzae protein d 1 μg ps5; 0.67-1.25 μg pd/dose; conjugate of streptococcus pneumoniae type 6b and haemophilus influenzae protein d 1 μg ps6b; 0.56-0.95 μg pd/dose; conjugate of streptococcus pneumoniae type 7f and haemophilus influenzae protein d 1 μg ps7f; 0.87-1.43 μg pd/dose; conjugate of streptococcus pneumoniae type 9v and haemophilus influenzae protein d 1 μg ps9v; 1.00-1.82 μg pd/dose; diphtheria toxoid (dt) carrier protein 3-6 μg dt/dose (total dt content); polysaccharide (ps) 16 μg/dose (total ps content); protein-d (pd) carrier protein (derived from non-typeable haemophilus influenzae) 9-16 μg pd/dose (total pd content); tetanus toxoid (tt) carrier protein 5-10 μg/dose (total tt content)

Reino Unido - inglês - myHealthbox

glaxosmithkline consumer healthcare - paracetamol, caffeine - tablets - 500 mg/65 mg - a mild analgesic and antipyretic formulated to give extra pain relief. the tablets are recommended for the treatment of most painful and febrile conditions, for example, headache, including migraine, backache, toothache, rheumatic pain and dysmenorrhoea, and the relief of the symptoms of colds, influenza and sore throat.

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - nicotine - medicated chewing gum - 20mg - drugs used in nicotine dependence - it is used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms including cravings during a quit attempt. permanent cessation of tobacco use is the eventual objective

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - nicotine - medicated chewing gum - 4mg - drugs used in nicotine dependence - e treatment of tobacco dependence by relief of nicotine withdrawal symptoms including cravings during a quit attempt